Zenocutuzumab
Zenocutuzumab (MCLA-128) is a bispecific humanized IgG1 antibody containing two different Fab arms, targeting extracellular domains of HER2 and HER3[1].
Product Specifications
CAS Number
[1969309-56-5]
Product Name Alternative
MCLA-128; PB4188; R040517
UNSPSC
12352203
Target
EGFR
Type
Inhibitory Antibodies
Related Pathways
JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/zenocutuzumab.html
Purity
99.9
Solubility
10 mM in DMSO
Smiles
[Zenocutuzumab]
Molecular Weight
(145.76 kDa)
References & Citations
[1]Alison M Schram, et al. Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements. Cancer Discov. 2022 May 2;12 (5) :1233-1247.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Launched
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS2018285-01 0.01 mg
Recombinant Von Willebrand Factor A Domain Containing Protein 1 (vWA1)
Ask
View Details 
MBS2018285-02 0.05 mg
Recombinant Von Willebrand Factor A Domain Containing Protein 1 (vWA1)
Ask
View Details MBS2018285-03 0.1 mg
Recombinant Von Willebrand Factor A Domain Containing Protein 1 (vWA1)
Ask
View Details 
MBS2018285-04 0.2 mg
Recombinant Von Willebrand Factor A Domain Containing Protein 1 (vWA1)
Ask
View Details MBS2018285-05 0.5 mg
Recombinant Von Willebrand Factor A Domain Containing Protein 1 (vWA1)
Ask
View Details 
MBS2018285-06 1 mg
Recombinant Von Willebrand Factor A Domain Containing Protein 1 (vWA1)
Ask
View Details